BioMarin to acquire Inozyme for $4.00 per share in cash, or $270M

BioMarin Pharmaceutical (BMRN) and Inozyme Pharma (INZY) announced that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transaction for a total consideration of approximately $270M. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the third quarter of 2025, subject to regulatory approval, successful completion of a tender offer and other customary closing conditions. Inozyme’s Board of Directors unanimously recommends that Inozyme’s stockholders tender their shares in the tender offer.